pLOG

2026-01-13

2025 PatientsForce Patient Support Service and Social Impact Report

AI-driven National Health Insurance Safety Net and Precision Health Journey

At the intersection of global healthcare cost pressures and Taiwan's National Health Insurance reform in 2025, PatientsForce positions itself as a "Strategic Market Access Bridge" within the healthcare ecosystem. We not only address the financial affordability of innovative medicines but also implement scalable patient medication support and healthcare journey management through AI technology.

Three Core Value Indicators for 2025:

  • The Ten-Billion Milestone: Cumulative medication subsidies facilitated through Patient Support Programs (PSP) have surpassed NT2.3 billion in 2025 alone.
  • Global ESG Leadership: Awarded the 2025 EcoVadis Sustainability Bronze Medal, with overall performance ranking in the top 23% of the global industry, while "Sustainable Procurement" soared into the top 4% elite tier.
  • High-Performance Operations: Developed and applied "Agentic AI" and automated customer service to enhance administrative efficiency, with an estimated annual target of saving over 200 man-days in labor hours, maintaining streamlined operations through an expert team.

 

Collaboration between the National Health Insurance review gap and the New Drug Fund

Taiwan's Cancer Registry report shows that the "cancer clock" has accelerated to one person diagnosed every 3 minutes and 48 seconds. Although the government established a NT$10 billion "Cancer New Drug Fund (CDF)" in 2025, a significant gap in patient needs remains during the "review gap period" between a new drug receiving certification and its official inclusion in National Health Insurance coverage.

PatientsForce's Role and Positioning:

  • NHI Safety Net: PatientsForce plays the "third role" in public-private partnerships within the National Health Insurance system. During the out-of-pocket period after a new drug's launch, we address the supply-demand time gap in the pharmaceutical economic market, alleviating the pressure of financial toxicity for nearly 10,000 cancer patients in 2025.
  • National Health Insurance (NHI) and CDF Connector: Given the limited budget of the NHI and CDF (estimated to cover only a portion of urgent needs), we have facilitated timely treatment for nearly 15,000 enrolled patients through PSP projects, ensuring market accessibility for innovative drugs before they are officially covered by insurance.

 

2025 Annual Operational Data: Service Regions and Department Distribution

PatientsForce demonstrated its coverage capabilities for medical network patient support services in Taiwan in 2025, ensuring that precision medical resources are no longer confined to urban centers.

📊 Key Metrics

Indicator Item

2025 Cumulative Data

Strategic value

Annual Number of Newly Enrolled Patients

>15,000

A steadily expanding foundation of Real-World Evidence (RWE)

Cumulative Total Number of Patients Served

>60,000人

Taiwan's largest PSP management platform

Annual Number of Subsidy Transactions Paid

>45,000 transactions

High-frequency, precise pharmaceutical logistics collaboration and compliance management

Total Number of Partnered Hospitals

>750 institutions

100% coverage of Taiwan's medical network (including medical centers)

Number of Partnered Physicians

>3,600 physicians

Covers Key Opinion Leaders (KOLs) across all specialties

Number of Service Drug Items

>90 items

Covers over 80% of high-value innovative specialty drugs

 

 

🔍 Regional and therapeutic area analysis

PatientsForce has become a primary qualified PSP provider for over 80% of the Top 15 global multinational pharmaceutical companies, and is a partner to Taiwan's listed biotech and pharmaceutical firms.

Oncology (70%):Focusing on targeted therapies and immunotherapy, effectively reducing treatment discontinuation rates for advanced cancer patients.
Chronic and Rare Diseases (30%):Including rare disease patient assistance programs, biologics, osteoporosis, and pediatric care, assisting physicians in improving patient treatment adherence.
Regional Centers (North/Central/South):Highly concentrated in Taiwan’s major medical centers, serving as core nodes for subsidy disbursement.
Remote Services (Remote Areas):Reached nearly 200 partner pharmacies and GP clinics via digital platforms in 2025, extending PSP services to community and home-care settings.
Cross-Hospital Coverage:Equipped with cross-system data integration capabilities, providing pharmaceutical companies with consistent project execution standards.

 

Professional Medical Management: The "Value-Added Care" Patient Journey for Precision Health

PatientsForce has upgraded its traditional drug subsidy management information platform (PharmaPass) to the "Generation 2.0 PSP Patient Support & Benefit System," providing value-added professional services throughout the patient medication journey and offering clients compliant, rapid-launch PSP services.

🛡️Details of Value-Added Services in Value-Based Healthcare

Consequently, many biotech companies are turning to the IPO market, private equity, and private credit. Compared to traditional M&A, this allows for greater operational flexibility and more R&D funding while enabling companies to retain control over critical drug development.

Precision Diagnosis Companion Services: The PSP clinical nursing consultancy team, in alignment with the trend of National Health Insurance (NHI) coverage for NGS testing, assists patients in identifying appropriate genetic profiles, shortening the time from diagnosis to the commencement of targeted therapy.

  1. Comprehensive Journey Management: Covering 8 core steps including companion diagnosis, nursing education, transportation booking, pre-consultation reminders, and home care, significantly improving treatment adherence.
  2. Adverse Event (AE) Reporting: Through real-time monitoring by professional care teams, assisting pharmaceutical companies in collecting high-quality Real-World Evidence (RWE) to provide data support for subsequent National Health Insurance (NHI) reimbursement based on real-world data.

 

AI Revolution: Defining New Standards for High-Efficiency Administration

AI Automated Auditing: Utilizing LLM (Large Language Model) to process tedious subsidy application document reviews, reducing administrative tasks from 3 to 5 business days to "second-level" response times, significantly improving the efficiency of patient medication collection.

  • OCR + NLP Intelligent Document Processing: Annually processing over 600,000 complex medical documents containing mixed Chinese and English data. Through AI models, processing speeds have been accelerated to the "second-level," ensuring data security and significantly reducing error rates.。
  • Scalable Operational Efficiency: The digital management platform saves 200 days of administrative man-hours annually, enabling the company to demonstrate exceptional employee efficiency while managing over **80 complex projects**.

 

ESG Leadership: 2025 EcoVadis Global Sustainability Rating Achievements

PatientsForce Group (Cai-Zhao Strategy) earned the EcoVadis Bronze Medal  in 2025, a key indicator used by multinational pharmaceutical companies to assess supply chain resilience.

🎖️EcoVadis Percentile Rank Analysis

  • Overall performance: Ranked in the top 23% of companies assessed globally.
  • Ethics: Ranked in the top 20%, demonstrating excellence in governance regarding information security and privacy (ISO 27001/27701) and transparent management.
  • Labor & Human Rights: Ranked in the top 27%, establishing a diverse and equitable workplace environment.
  • Sustainable Procurement: Ranked in the top 4% globally, demonstrating industry leadership in integrating pharmaceutical supply chains and promoting paperless green logistics.

 

2026 Outlook: Expanding Asia-Pacific Patient Support Markets and Patient-Provider Empowerment

Looking ahead to 2026, PatientsForce will continue to focus on expanding the capacity and value of patient support services as its core objective,

  1. Expanding support services to "Named Patient" programs: Establishing an international network for access to specialty medicines to help urgent-need patients in Taiwan—whose required medications are not yet licensed or covered by National Health Insurance—obtain prescribed drugs in a timely manner. Shortening the special import process through digital management and direct coordination with international pharmaceutical companies.
  2. Technology-driven Home Care (Escort & Home Care): Integrating AIoT remote smart care with nursing manpower for "Hospital at Home" initiatives. Utilizing real-time physiological data alerts and accessible community nursing resources.

Let us utilize the breadth of technology and the warmth of professional healthcare to reduce the burden on every patient using new medications and expand the coverage of precision care. This is not only a revolution in medical accessibility but also a long-term commitment to every life.